Navigation Links
Mylan Launches First Generic Version of Xopenex(R) Inhalation Solution (Concentrate), 0.25%
Date:9/1/2009

PITTSBURGH, Sept. 1 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched levalbuterol inhalation solution USP (Concentrate), 0.25%, (1.25 mg/0.5 mL). Mylan, which has already launched the product, will market this product with 180 days of exclusivity.

This product, which is indicated for the treatment or prevention of bronchospasm in patients over 6 years old with reversible obstructive airway disease, is the first generic version of Sepracor Inc.'s Xopenex(R) Inhalation Solution (Concentrate), 0.25%, to be approved by the U.S. Food and Drug Administration (FDA). According to IMS Health, Xopenex Inhalation Solution (Concentrate), 0.25% had total U.S. sales of approximately $18.3 million for the 12 months ending June 30, 2009.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; operates a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
2. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
3. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
4. President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
5. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
6. Mylan Announces Enhancements to Executive Management Team
7. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
8. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
9. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 06, 2016 , ... In honor of Military Spouse Appreciation ... and the National Military Family Association, a nonprofit that works to strengthen and ... scholarship recipient of 2016. , “Being awarded this scholarship by Career Step, ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... at CareFirst Blue Cross BlueShield and Former Principal Deputy Administrator at Centers for ... an Anthem Company; Steve Ondra, MD, Chief Medical Officer at Health Care Service ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... injectables (LAIs), today announced a development collaboration with the Australian critical medicine ... mental disorders such as schizophrenia. , LAI medicines can offer improved therapeutic benefits ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term warfarin ... first offering the procedure in April of 2015, Florida Hospital Pepin Heart Institute ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... some macroalgae can use ultraviolet light A (UV-A) for photosynthesis, researchers Juntian Xu ... red, green, and brown seaweeds. The pair observed that when photosynthetically active radiation ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research ... the  "Europe Thrombocytopenia Market and Competitive ... their offering.       (Logo: ... latest research Europe Thrombocytopenia Market and ... comprehensive insights into Thrombocytopenia pipeline products, ...
(Date:5/4/2016)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... First Quarter 2016 Highlights , Generated Cash ... Flow") of $13.6 million for the first quarter of ... for the first quarter of 2016; , Paid ...
(Date:5/4/2016)... Israel , May 4, 2016 ... BiondVax,s CEO, Dr. Ron Babecoff , will be attending ... York City . On Thursday, May 5, ... a conference presented by Joseph Gunner & Co, ... The BiondVax presentation that Dr. Babecoff will be using is ...
Breaking Medicine Technology: